IVF Success: Male vs. Female Factor Infertility—What You Need to Know

In vitro fertilization (IVF) addresses infertility from male factors, female factors, combined factors, or unexplained causes. Both partners contribute equally to the diagnostic evaluation.

Male Factor Infertility (~30–40%)

  • Spermatogenic defects: Oligozoospermia (<15M/mL), asthenozoospermia (<40% motility), teratozoospermia (<4% normal morphology), cryptozoospermia, azoospermia (obstructive vs. non-obstructive).
  • Functional defects: DNA fragmentation (SCD, TUNEL), acrosome dysfunction, epigenetic abnormalities.
  • IVF/ICSI solutions: ICSI (intracytoplasmic sperm injection) bypasses most fertilization barriers; TESE/microTESE for non-obstructive azoospermia; PGT-A for aneuploidy screening.

Female Factor Infertility (~30–40%)

  • Ovulatory disorders: PCOS (70% of anovulation), hypothalamic amenorrhea, POI, thyroid, hyperprolactinemia.
  • Tubal/peritoneal: Blocked tubes (PID, endometriosis, prior surgery), hydrosalpinx (toxic to embryos — salpingectomy before IVF).
  • Uterine: Fibroids (submucosal), polyps, adenomyosis, congenital anomalies (septate), thin endometrium.
  • Endometriosis: Inflammatory milieu impairs oocyte quality, implantation; staging guides surgery vs. IVF.
  • Age-related decline: Oocyte quantity (AMH, AFC) & quality (aneuploidy ↑ exponentially >35y).

Combined / Unexplained (~20–30% / 10–20%)

  • Both partners have subclinical defects (e.g., borderline sperm + mild endometriosis).
  • Unexplained: Normal standard testing; may reflect subtle gamete/embryo/endometrial dysfunction.

IVF Process Overview

  1. Controlled ovarian stimulation (COH) → monitoring → trigger.
  2. Oocyte retrieval (TVUS-guided).
  3. Fertilization: Conventional IVF (50–100k sperm/oocyte) or ICSI (1 sperm injected).
  4. Embryo culture to blastocyst (Day 5–6); grading (morphology, time-lapse, PGT-A).
  5. Fresh or frozen embryo transfer (FET preferred for OHSS risk, endometrial synchrony).
  6. Luteal support (progesterone ± estradiol).
  7. Pregnancy test (β-hCG) ~9–11d post-transfer.

Success Determinants

  • Female age (primary driver: <35y ~50% LBR/transfer; 40y ~10–15%; >42y ~3–5% with own oocytes).
  • Ovarian reserve (AMH, AFC).
  • Embryo quality (morphology, euploidy via PGT-A).
  • Uterine receptivity.
  • Lab quality, protocol individualization.

Key Message

IVF is not "female treatment." Comprehensive couples' evaluation directs therapy: ICSI for male factor, PGT-A for age/aneuploidy, surgery for structural issues, donor gametes if needed. Shared decision-making with a reproductive endocrinologist optimizes outcomes.

Baby Health - Related Articles